Relacorilant
- Generic Name
- Relacorilant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22F4N6O3S
- CAS Number
- 1496510-51-0
- Unique Ingredient Identifier
- 2158753C7E
- Background
Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
Better Biomarkers for Better Medicines
Biomarkers are crucial in healthcare and drug development, aiding in disease prediction, monitoring, and treatment response assessment. Despite challenges in discovery and validation, they enhance clinical trial precision and cost-effectiveness. Omics technologies and collaborative efforts are key to overcoming these challenges, with companies like Mission Bio and Precision for Medicine leading advancements.
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
Corcept Therapeutics completed enrollment in the phase III ROSELLA study for relacorilant combined with Abraxane for recurrent, platinum-resistant ovarian cancer, expecting progression-free survival data by 2024-end. Relacorilant is also in phase III studies for Cushing’s syndrome and adrenal cancer, with data expected in 2024. Corcept's shares dropped 25.4% this year.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath